Genesis Biopharma Announces Issuance of European Patent for Anti-CD55 Targeted Cancer Therapy

MANHATTAN BEACH, Calif., Nov. 4, 2010 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that the European Patent Office (EPO) has issued EPO Patent Grant No. 1565494 providing broad coverage on Genesis anti-CD55 antibodies for use as a therapeutic treatment in multiple cancers.  The patent, which expires in 2023, is registered to the U.K.-based Cancer Research Technology, Ltd. (CRT) and licensed to Genesis Biopharma.

The patent "CD55-Interaction Partners and the Uses Thereof" covers use of the Genesis anti-CD55 antibodies both as a monotherapy and as a combination therapy, including their use in combination with marketed antibody therapies.  Patent coverage includes France, Germany, United Kingdom, Spain, Italy and Switzerland.  Genesis Biopharma is pursuing related patent applications for its anti-CD55 program in the U.S., Japan, Hong Kong, Australia and Canada.  

"This patent supports our intellectual property strategy for our anti-CD55 program and provides broad technology coverage in the major European healthcare market," said Robert Brooke, Genesis Biopharma president and CEO.  "It also bodes well for our pending patent applications in other nations."  

Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid tumors.  The therapy could provide a safe alternative to toxic chemotherapy regimens.  The company is initially addressing metastatic colorectal cancer and lymphoma, and is making progress toward an IND filing with the U.S. Food and Drug Administration (FDA).  Genesis Biopharma plans to seek partnerships with pharmaceutical and biotechnology companies to support clinical development programs at the earliest appropriate time.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Brooke

http://www.profnetconnect.com/robert_brooke

SOURCE Genesis Biopharma, Inc.

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.